In the PROfound trial, a crossover randomized phase III trial, patients with mCRPC with BRCA1, BRCA2, and ATM tumor alterations showed improved survival when treated first-line with olaparib compared to enzalutamide or abiraterone (19.1 months vs. 14.7 months, HR = 0.69; p = 0.02) [71]. This evidence concerns the gene BRCA2 and neoplasm.